Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric I Felner

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2026
Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period StudyJennifer L Miller, Nicola Bridges, Eric I Felner, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Diabetes & Endocrinology|July 2, 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen E Gitelman, Brian N Bundy, Ele Ferrannini, et al.
Obesity (Silver Spring, Md.)|November 3, 2023
Diazoxide choline extended-release tablet in people with Prader-Willi syndrome: results from long-term open-label studyJennifer L Miller, Evelien Gevers, Nicola Bridges, et al.
The Journal of Clinical Endocrinology and Metabolism|January 3, 2026
Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized, Double-Blind, Withdrawal Period StudyJennifer L Miller, Nicola Bridges, Eric I Felner, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Pageof 4